|
 As a result, the U.S. biotechnology company said it would not seek
an additional approval for Revlimid for that use, and its shares
fell more than 2 percent.
Revlimid, a multiple myeloma treatment with annual sales of about $6
billion, was being tested versus a placebo in patients whose diffuse
large B-cell lymphoma had responded to initial treatment with
Roche's Rituxan and chemotherapy.
Approval as a maintenance therapy, used to prevent recurrence and
improve survival, can significantly add to sales as the drugs are
taken long term.
While the Revlimid study delayed progression of the disease, no
survival benefit was seen, the company said. The trial was conducted
along with the Lymphoma Study Association.
Celgene said it will continue to study Revlimid in a variety of
lymphomas.
(Reporting by Bill Berkrot; Editing by Sandra Maler)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
|
